Stockscreener 앱 받기
4.90
1.80%
-0.09
시간 외 거래:
4.90
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IOVA|Iovance Biotherapeutics Inc|Price:4.990|Chg%:-0.140 - TradingKey
Iovance Biotherapeutics Inc (IOVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Iovance Biotherapeutics Inc Revenue Breakdown – BX:IOVA - TradingView
TradingKey - TradingKey
Iovance Biotherapeutics Inc Revenue Breakdown – MIL:1IOVA - TradingView
Iovance Shares Close Unchanged After Choppy Trading; 2026 Sales Target Puts Pressure on Growth Pace - TechStock²
Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance Biotherapeutics (IOVA) Rallies On Undervalued Claims, Is The Market Still Missing Fair Value? - Sahm
Iovance Biotherapeutics Market Sentiment - Benzinga España
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 71.54% Potential Upside in Biotech - DirectorsTalk Interviews
Iovance Biotherapeutics Inc (IOVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada
Iovance Biotherapeutics stock hits 52-week high at $5.64 By Investing.com - Investing.com South Africa
Iovance Biotherapeutics stock hits 52-week high at $5.64 - Investing.com
Iovance Biotherapeutics (IOVA) Stock Looks Fully Priced Despite Strong 117% Returns - Sahm
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Why Is IOVA Stock Falling Today? - Stocktwits
Iovance (NASDAQ:IOVA) advances 18% in a week, drawing attention to Amtagvi sales goals - TechStock²
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches - TechStock²
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Gives 17 New Employees Options That Vest Over 3 Years - Stock Titan
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance shares surge as attention shifts to Amtagvi’s second-half sales target - TechStock²
$4.659 | Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock Price Today - Binance
ETFs Investing in Iovance Biotherapeutics Inc Stocks - TradingView
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy) (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value - TechStock²
IOVA Stock Holds Range As Capital Plans And Hiring Ramp Up - StocksToTrade
Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight - PR Newswire
IOVA Stock Price, Quote & Chart - ChartMill
Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative - Sahm
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note - Insider Monkey
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
This Stock Is Up 74% This Year: Is It Too Late to Buy? - The Motley Fool
Enterprise value to revenue forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
1.97%
0.83%
자본화:
|
볼륨(24시간):